Valion Bio Inc
tivichealth.comValion Bio Inc (VBIO) is a clinical-stage biopharmaceutical company developing drug candidates for acute radiation syndrome and related indications. The company generates no commercial revenue; its spending consists of research and development costs covering personnel, third-party contractor services, cell line verification, drug product and drug substance development, and maintenance of limited in-house research facilities, alongside selling, general and administrative expenses. Its lead candidate is Entolimod, a TLR5 agonist licensed from Statera in February 2025 under a License Agreement. Clinical data shows Entolimod produces rapid, dose-dependent elevations in G-CSF, IL-6, and absolute neutrophil count in humans, with pharmacodynamic profiles concordant with non-human primate data, forming the basis for an Animal Rule regulatory pathway. The company is headquartered in San Antonio, Texas, where it also leases an approximately 8,024 square foot microbial facility under an eight-year lease signed March 13, 2026. Valion Bio has financed operations through equity offerings, including public offerings that closed in 2023, 2024, and 2025.
Products & Services
Entolimod: a TLR5 agonist licensed from Statera in February 2025, in development for acute radiation syndrome (ARS) under the FDA Animal Rule pathway. Clinical data as of the 10-K filed 2026-03-30 documents dose-dependent neutrophil mobilization and cytokine response (G-CSF, IL-6) in humans consistent with non-human primate efficacy data.
Revenue Model
Pre-revenue clinical-stage company. No commercial product sales as of the fiscal year ended December 31, 2025. Operations are funded through equity offerings. R&D and SG&A are the primary expense categories.
Customers & Markets
No commercial customers as of the fiscal year ended December 31, 2025. Target end market is treatment of acute radiation syndrome, with potential relevance to government emergency preparedness procurement.
Geographic Exposure
Headquartered in San Antonio, Texas. Operations described as U.S.-based in the 10-K filed 2026-03-30. Some exposure to global supply chain disruptions noted in the filing.
Financial Snapshot
Loading...
